Article Menu

Export Article

More by Authors Links

Article Data

  • Views 955
  • Dowloads 102

Case Reports

Open Access

Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII

  • S. Sajdak1,*,
  • R. Moszynski1
  • T. Opala1

1Division of Gynecological Surgery, Department of Gynecology and Obstetrics, Karol Marcinkowski University of Medical Sciences, Poznan, Poland

DOI: 10.12892/ejgo200204325 Vol.23,Issue 4,July 2002 pp.325-326

Published: 10 July 2002

*Corresponding Author(s): S. Sajdak E-mail: Kgo@gpsk.am.poznan.pl

PDF (212.92 kB) View Full-text

Abstract

The authors report two cases of successful employment of human recombinant activated factor VII in gynecological oncological patients (endometrial cancer and vaginal sarcoma) without pre-existing coagulopathy. They conclude that recombinant factor VIIa may be an important and effective drug in severe bleeding in gynecological oncology.

Keywords

Recombinant factor Vila; Coagulation; Hemorrhage; Cancer of endometrium; Vaginal sarcoma

Cite and Share

S. Sajdak,R. Moszynski,T. Opala. Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII. European Journal of Gynaecological Oncology. 2002. 23(4);325-326.

URL:

https://www.ejgo.net/articles/10.12892/ejgo200204325

References

[1] Friederich P. W., Geerdink M. G., Spataro M. et al.: "The effect of the administration of recombinant activated factor VII (NovoSeven®) on perioperativ blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study". Blood Coagul. and Fibrinol., 2000, 11, 129.

[2] Hay C. R., Negrier C., Ludlam C. A.: "The treatment of bleedmg in acquired haemophilia with recombinant factor VIIa: a multicenter study". Thromb. Haemostat, 1997, 79, 1463.

[3] Kenet G., Walden R., Eldad A., Martinowitz U.: "Treatment of traumatic bleeding with recombinant factor VIIa". The Lancet, 1999, 354, 1879.

[4] Negrier C., Linhart A.: "Overall experience with NovoSeven®" Blood Coagul. and Fibrinol., 2000, 11, 19.

[5] Pickard J. D., Kirkpatrick P. J., Melsoen T. et al.: "Potential role of NovoSeven(r) in the prevention of re bleeding following aneurysmal subarachnoid haemorrhage". Blood Coagulation and Fibrinolysis, 2000, 11, 117.

[6] Shapiro A. D., Gilchrist G. S., Hoots W. K. et al.: "Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia patients with Inhibitors Undergoing Surgery". Thromb Haemostat, 1998, 80, 773.

[7] Liem A. K., Biesma D. H., Ernst S. M., Schepens M.A.: "Recombinant Activated Factor VII for False Aneurysms in patients with Normal Haemostatic Mechanisms". Thromb. Haemostat., 1999, 82, 150.

[8] Vlot A. J., Ton E., Mackaay A. J. et al.: "Treatment of a Severely Bleeding Patient without Preexisting Coagulopathy with Activated Recombinant Factor VII". Am. J. of Med., 2000, 108,421

[9] White B., McHale J., Ravi N. et al.: "Successful use of Recombinant FVIIa (NovoSeven(r)) in the Management of Intractable Post-surgical Intra-abdominal haemorrhage". Brit. J. of Haemathol., 1999, 107, 677.

Submission Turnaround Time

Top